ArticleNPJ precision oncology2025

MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways.

Wenhao Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.